2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension
Open accessThe DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
It has been almost 5 years since the publication of the 2010 hypertension guidelines of the Taiwan Society of Cardiology (TSOC). There is new evidence regarding the management of hypertension, including randomized controlled trials, non-randomized trials, post-hoc analyses, subgroup analyses, retrospective studies, cohort studies, and registries. More recently, the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) published joint hypertension guidelines in 2013. The panel members who were appointed to the Eighth Joint National Committee (JNC) also published the 2014 JNC report. Blood pressure (BP) targets have been changed; in particular, such targets have been loosened in high risk patients. The Executive Board members of TSOC and the Taiwan Hypertension Society (THS) aimed to review updated information about the management of hypertension to publish an updated hypertension guideline in Taiwan. We recognized that hypertension is the most important risk factor for global disease burden. Management of hypertension is especially important in Asia where the prevalence rate grows faster than other parts of the world. In most countries in East Asia, stroke surpassed coronary heart disease (CHD) in causing premature death. A diagnostic algorithm was proposed, emphasizing the importance of home BP monitoring and ambulatory BP monitoring for better detection of night time hypertension, early morning hypertension, white-coat hypertension, and masked hypertension. We disagreed with the ESH/ESH joint hypertension guidelines suggestion to loosen BP targets to <140/90 mmHg for all patients. We strongly disagree with the suggestion by the 2014 JNC report to raise the BP target to <150/90 mmHg for patients between 60-80 years of age. For patients with diabetes, CHD, chronic kidney disease who have proteinuria, and those who are receiving antithrombotic therapy for stroke prevention, we propose BP targets of <130/80 mmHg in our guidelines. BP targets are <140/90 mmHg for all other patient groups, except for patients ≥80 years of age in whom a BP target of <150/90 mmHg would be optimal. For the management of hypertension, we proposed a treatment algorithm, starting with life style modification (LSM) including S-ABCDE (Sodium restriction, Alcohol limitation, Body weight reduction, Cigarette smoke cessation, Diet adaptation, and Exercise adoption). We emphasized a low-salt strategy instead of a no-salt strategy, and that excessively aggressive sodium restriction to <2.0 gram/day may be harmful. When drug therapy is considered, a strategy called "PROCEED" was suggested (Previous experience, Risk factors, Organ damage, Contraindications or unfavorable conditions, Expert's or doctor's judgment, Expenses or cost, and Delivery and compliance issue). To predict drug effects in lowering BP, we proposed the "Rule of 10" and "Rule of 5". With a standard dose of any one of the 5 major classes of anti-hypertensive agents, one can anticipate approximately a 10-mmHg decrease in systolic BP (SBP) (Rule of 10) and a 5-mmHg decrease in diastolic BP (DBP) (Rule of 5). When doses of the same drug are doubled, there is only a 2-mmHg incremental decrease in SBP and a 1-mmHg incremental decrease in DBP. Preferably, when 2 drugs with different mechanisms are to be taken together, the decrease in BP is the sum of the decrease of the individual agents (approximately 20 mmHg in SBP and 10 mmHg in DBP). Early combination therapy, especially single-pill combination (SPC), is recommended. When patient's initial treatment cannot get BP to targeted goals, we have proposed an adjustment algorithm, "AT GOALs" (Adherence, Timing of administration, Greater doses, Other classes of drugs, Alternative combination or SPC, and LSM + Laboratory tests). Treatment of hypertension in special conditions, including treatment of resistant hypertension, hypertension in women, and perioperative management of hypertension, were also mentioned. The TSOC/THS hypertension guidelines provide the most updated information available in the management of hypertension. The guidelines are not mandatory, and members of the task force fully realize that treatment of hypertension should be individualized to address each patient's circumstances. Ultimately, the decision of the physician decision remains of the utmost importance in hypertension management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure
Appel, L. J., Moore, T. J., Obarzanek, E., Vollmer, W. M., Svetkey, L. P., Sacks, F. M., Bray, G. A., Vogt, T. M., Cutler, J. A., Windhauser, M. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361601 · Cited by 5,981
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699 · cited 2×
“Interestingly, the addition of PCI to optimal medical therapy as an initial management strategy did not reduce the risk of death or myocardial infarction.(162) This study confirmed that, in the era of bare metal stent, optimal medical therapy including aggressive BP-lowering is as effective as PCI in the treatment of…”
MethodThe Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Circulation · doi:10.1161/01.cir.0000154900.76284.f6 · Cited by 3,985
(2013) · doi:10.1097/01.aog.0000437382.03963.88 · Cited by 3,961
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
O'Donnell, M. J., Xavier, D., Liu, L., Zhang, H., Chin, S. L., Rao-Melacini, P., Rangarajan, S., Islam, S., Pais, P., McQueen, M. J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60834-3 · Cited by 3,448
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“Solid evidence has also shown that aldosterone antagonists significantly reduce mortality in patients with severe systolic heart failure,(283) or with prior myocardial infarction,(284) and even in patients with mild systolic heart failure.(285) However, the enrolled patients in these clinical trials were basically nor…”
BackgroundA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Treatment of hypertension in patients 80 years of age or older
Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092 · cited 5×
“Fewer serious adverse events were reported in the active-treatment group.(200)”
BackgroundMethodInfluentialStaessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Spironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809 · cited 1×
“In a similar but larger scale randomized clinical trial in patients with heart failure and a preserved ejection fraction (TOPCAT), treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome including death from cardiovascular causes.(287) Treatment-resistant hypertension…”
BackgroundLaw, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Effect of Aerobic Exercise on Blood Pressure: A Meta-Analysis of Randomized, Controlled Trials
Whelton, S. P., Chin, A., Xin, X., & He, J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-7-200204020-00006 · Cited by 1,970
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f0580f · Cited by 1,837
Measuring the global burden of disease
Murray, C. J. L., & Lopez, A. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1201534 · Cited by 1,818
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773 · cited 1×
“However, hydralazine in combination with isosorbide dinitrate, is effective in AfricanAmericans who have symptomatic heart failure.(359) Because of the severity of adverse effects with minoxidil, its usage is limited to persons with severe hypertension unresponsive to other treatment.”
BackgroundRapsomaniki, E., Timmis, A., George, J., Pujades-Rodriguez, M., Shah, A. D., Denaxas, S., White, I. R., Caulfield, M. J., Deanfield, J. E., Smeeth, L., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60685-1 · Cited by 1,643 · cited 2×
“25 million subjects, initially free from cardiovascular disease, the lowest risk for cardiovascular disease was in people with SBP of 90114 mmHg and DBP of 60-74 mmHg, without any evidence of J-curve phenomenon.(32) In the Multiple Risk Factor Intervention Trial (MRFIT) which enrolled 332,554 subjects without end orga…”
BackgroundResultAdherence to a DASH-Style Diet and Risk of Coronary Heart Disease and Stroke in Women
Fung, T. T. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.7.713 · Cited by 1,567
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“280 In addition, the prevalence of primary aldosteronism in hypertensive patients was reported to increase along with hypertension stages.(281) Hypertensive patients in the real world practice are less commonly to be treated with aldosterone antagonists, given that almost 15-20% of stage II-III patients have aldostero…”
BackgroundPrevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004
Ong, K. L., Cheung, B. M. Y., Man, Y. B., Lau, C. P., & Lam, K. S. L. (2007) · Hypertension · doi:10.1161/01.hyp.0000252676.46043.18 · Cited by 1,395
Influence of Weight Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003) · Hypertension · doi:10.1161/01.hyp.0000094221.86888.ae · Cited by 1,391
Franklin, S. S., Larson, M. G., Khan, S. A., Wong, N. D., Leip, E. P., Kannel, W. B., & Levy, D. (2001) · Circulation · doi:10.1161/01.cir.103.9.1245 · Cited by 1,390
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319 · cited 1×
“The trial was prematurely terminated due to a non-significant increase in primary endpoints, and an increase in adverse events, such as hyperkalemia and hypotension.(353) The RCT testing the effect of aliskiren, on top of ACE inhibitors or ARBS, in heart failure had a neutral effect, but had increased adverse events,…”
BackgroundKario, K., Pickering, T. G., Umeda, Y., Hoshide, S., Hoshide, Y., Morinari, M., Murata, M., Kuroda, T., Schwartz, J. E., & Shimada, K. (2003) · Circulation · doi:10.1161/01.cir.0000056521.67546.aa · Cited by 1,250
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Global Sodium Consumption and Death from Cardiovascular Causes
Mozaffarian, D., Fahimi, S., Singh, G. M., Micha, R., Khatibzadeh, S., Engell, R. E., Lim, S., Danaei, G., Ezzati, M., & Powles, J. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304127 · Cited by 1,218
Cook, N. R., Cutler, J. A., Obarzanek, E., Buring, J. E., Rexrode, K. M., Kumanyika, S. K., Appel, L. J., & Whelton, P. K. (2007) · BMJ · doi:10.1136/bmj.39147.604896.55 · Cited by 1,179 · cited 3×
“The most important long term intervention trial for effects of dietary sodium reduction on cardiovascular disease outcomes came from TOHP I and TOHP II trials.(221) In these trials, the risk of cardiovascular event was 30% lower among those in the intervention group.”
Background2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk
Eckel, R. H., Jakicic, J. M., Ard, J. D., de Jesus, J. M., Houston Miller, N., Hubbard, V. S., Lee, I.-M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.003 · Cited by 1,160
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension
Clement, D. L., De Buyzere, M. L., De Bacquer, D. A., de Leeuw, P. W., Duprez, D. A., Fagard, R. H., Gheeraert, P. J., Missault, L. H., Braun, J. J., Six, R. O., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022273 · Cited by 1,085
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)
(2014) · Hypertension Research · doi:10.1038/hr.2014.20 · Cited by 1,049
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring
Parati, G., Stergiou, G., O’Brien, E., Asmar, R., Beilin, L., Bilo, G., Clement, D., de la Sierra, A., de Leeuw, P., Dolan, E., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000221 · Cited by 1,021
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Sega, R., Facchetti, R., Bombelli, M., Cesana, G., Corrao, G., Grassi, G., & Mancia, G. (2005) · Circulation · doi:10.1161/01.cir.0000160923.04524.5b · Cited by 1,009
Cornelissen, V. A., & Fagard, R. H. (2005) · Hypertension · doi:10.1161/01.hyp.0000184225.05629.51 · Cited by 1,005
Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H., Black, H. R., Hamilton, B. P., Holland, J., Nwachuku, C., et al. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.02045.x · Cited by 979
Wald, D. S., Law, M., Morris, J. K., Bestwick, J. P., & Wald, N. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.038 · Cited by 938
Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events
O'Donnell, M., Mente, A., Rangarajan, S., McQueen, M. J., Wang, X., Liu, L., Yan, H., Lee, S. F., Mony, P., Devanath, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311889 · Cited by 886
KARAMANOGLU, M., O'ROURKE, M. F., AVOLIO, A. P., & KELLY, R. P. (1993) · European Heart Journal · doi:10.1093/eurheartj/14.2.160 · Cited by 873 · cited 1×
“All the traditional ways of measuring BP, including office BP measurement, HBPM, and ABPM, use recordings from the brachial arteries, and may be different from the central BP measured in the ascending aorta or carotid arteries, due to the well-recognized BP amplification from the central aorta to the peripheral arteri…”
MethodAssociation of Urinary Sodium and Potassium Excretion with Blood Pressure
Mente, A., O'Donnell, M. J., Rangarajan, S., McQueen, M. J., Poirier, P., Wielgosz, A., Morrison, H., Li, W., Wang, X., Di, C., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311989 · Cited by 858
Assessment and management of blood-pressure variability
Parati, G., Ochoa, J. E., Lombardi, C., & Bilo, G. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.1 · Cited by 853
de la Sierra, A., Segura, J., Banegas, J. R., Gorostidi, M., de la Cruz, J. J., Armario, P., Oliveras, A., & Ruilope, L. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168948 · Cited by 809
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
Yusuf, S., Diener, H.-C., Sacco, R. L., Cotton, D., Ôunpuu, S., Lawton, W. A., Palesch, Y., Martin, R. H., Albers, G. W., Bath, P., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804593 · Cited by 785
Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904179 · Cited by 772
Dickinson, H. O., Mason, J. M., Nicolson, D. J., Campbell, F., Beyer, F. R., Cook, J. V., Williams, B., & Ford, G. A. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000199800.72563.26 · Cited by 759
Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials
Xin, X., He, J., Frontini, M. G., Ogden, L. G., Motsamai, O. I., & Whelton, P. K. (2001) · Hypertension · doi:10.1161/hy1101.093424 · Cited by 738
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710
Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension
Bisognano, J. D., Bakris, G., Nadim, M. K., Sanchez, L., Kroon, A. A., Schafer, J., de Leeuw, P. W., & Sica, D. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.008 · Cited by 600
Predictive Role of the Nighttime Blood Pressure
Hansen, T. W., Li, Y., Boggia, J., Thijs, L., Richart, T., & Staessen, J. A. (2011) · Hypertension · doi:10.1161/hypertensionaha.109.133900 · Cited by 597
Self-citationElmer, P. J., Obarzanek, E., Vollmer, W. M., Simons-Morton, D., Stevens, V. J., Young, D. R., Lin, P.-H., Champagne, C., Harsha, D. W., Svetkey, L. P., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00007 · Cited by 596 · cited 1×
“It is generally believed that the BPlowering effect of LSM is equivalent to drug monotherapy.(210) If applied appropriately, LSM can delay drug therapy in patients with stage 1 hypertension, allowing reduction in the number and doses of anti-hypertension drugs.”
Urinary sodium and potassium excretion and risk of cardiovascular events
O'Donnell, M. J., Yusuf, S., Mente, A., Gao, P., Mann, J. F., Teo, K., McQueen, M., Sleight, P., Sharma, A. M., Dans, A., et al. (2011) · JAMA · doi:10.1001/jama.2011.1729 · Cited by 564
Gradman, A. H., Schmieder, R. E., Lins, R. L., Nussberger, J., Chiang, Y., & Bedigian, M. P. (2005) · Circulation · doi:10.1161/01.cir.0000156466.02908.ed · Cited by 521
Dagenais, G. R., Pogue, J., Fox, K., Simoons, M. L., & Yusuf, S. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69201-5 · Cited by 514
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., & Porcellati, C. (2004) · Hypertension · doi:10.1161/01.hyp.0000125726.92964.ab · Cited by 510
European Society of Hypertension Practice Guidelines for home blood pressure monitoring
Parati, G., Stergiou, G. S., Asmar, R., Bilo, G., de Leeuw, P., Imai, Y., Kario, K., Lurbe, E., Manolis, A., Mengden, T., et al. (2010) · Journal of Human Hypertension · doi:10.1038/jhh.2010.54 · Cited by 482 · cited 4×
“A minimum of 12 measurements and up to 25 measurements over a few days might be desirable.56 Two morning readings and 2 evening readings for 7 days immediately before each visit, excluding the readings from the first day, would be measured and stored in devices for HBPM.57 Thus, there would be 12 readings either in th…”
BackgroundInfluentialHansen, T. W., Thijs, L., Li, Y., Boggia, J., Kikuya, M., Björklund-Bodegård, K., Richart, T., Ohkubo, T., Jeppesen, J., Torp-Pedersen, C., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140798 · Cited by 480
Self-citationPIERDOMENICO, S., LAPENNA, D., BUCCI, A., DITOMMASO, R., DIMASCIO, R., MANENTE, B., CALDARELLA, M., NERI, M., CUCCURULLO, F., & MEZZETTI, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.05.014 · Cited by 409
McManus, R. J., Mant, J., Haque, M. S., Bray, E. P., Bryan, S., Greenfield, S. M., Jones, M. I., Jowett, S., Little, P., Penaloza, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.10057 · Cited by 408
Graudal, N., Jürgens, G., Baslund, B., & Alderman, M. H. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu028 · Cited by 407 · cited 1×
“This J-shape association has been reported in other studies,(218) and a recent meta-analysis.(219) In fact, in a prospective cohort study in Taiwan a significant J-shape relationship between urinary sodium excretion and the risk of hypertension has also been observed, and the nadir of the Jshape was around 100 mmol (2.”
ResultThom, S. (2013) · JAMA · doi:10.1001/jama.2013.277064 · Cited by 405 · cited 2×
“SPC of anti-hypertensive drugs, statin, and aspirin was tested in the UMPIRE trial.(380) Use of SPC resulted in significantly improved medication adherence.”
BackgroundMethodNiiranen, T. J., Hänninen, M.-R., Johansson, J., Reunanen, A., & Jula, A. M. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149336 · Cited by 390
Aerobic Exercise Reduces Blood Pressure in Resistant Hypertension
Dimeo, F., Pagonas, N., Seibert, F., Arndt, R., Zidek, W., & Westhoff, T. H. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.197780 · Cited by 370 · cited 1×
“A recent RCT in patients with resistant hypertension, consisting of walking on a treadmill 3 times weekly for 8-12 weeks, has demonstrated a 6/3 mmHg reduction in ABPM compared with sedentary control group.(410) Drug therapy for TRH should begin with optimization of diuretic use.”
MethodMajor Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Hylek, E. M., Held, C., Alexander, J. H., Lopes, R. D., De Caterina, R., Wojdyla, D. M., Huber, K., Jansky, P., Steg, P. G., Hanna, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.549 · Cited by 344
Pratt-Ubunama, M. N., Nishizaka, M. K., Boedefeld, R. L., Cofield, S. S., Harding, S. M., & Calhoun, D. A. (2007) · Chest · doi:10.1378/chest.06-1442 · Cited by 331
Diagnostic Thresholds for Ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk
Kikuya, M., Hansen, T. W., Thijs, L., Björklund-Bodegård, K., Kuznetsova, T., Ohkubo, T., Richart, T., Torp-Pedersen, C., Lind, L., Ibsen, H., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.662254 · Cited by 314
Stergiou, G. S., Asayama, K., Thijs, L., Kollias, A., Niiranen, T. J., Hozawa, A., Boggia, J., Johansson, J. K., Ohkubo, T., Tsuji, I., et al. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02741 · Cited by 304
Ward, A. M., Takahashi, O., Stevens, R., & Heneghan, C. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834e4aed · Cited by 296
Whelton, P. K. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1401 · Cited by 290 · cited 1×
“, 2015 Guidelines of the T Management of Hypertension, Journal of the Chinese Medical Association (2014 ALLHAT, patients with impaired fasting glucose actually have significantly less CHD events in chlorthalidone group compared with the amlodipine group in the 4 to 8-year followup period of ALLHAT, in spite of an incr…”
ResultBangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290
Reboldi, G., Gentile, G., Angeli, F., Ambrosio, G., Mancia, G., & Verdecchia, P. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283469976 · Cited by 275
Bliziotis, I. A., Destounis, A., & Stergiou, G. S. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283531eaf · Cited by 261
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.046 · Cited by 244
Feldman, R. D., Zou, G. Y., Vandervoort, M. K., Wong, C. J., Nelson, S. A. E., & Feagan, B. G. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.123455 · Cited by 239
Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension
de Souza, F., Muxfeldt, E., Fiszman, R., & Salles, G. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.140988 · Cited by 234
Makani, H., Messerli, F. H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R. S., & Bangalore, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.034 · Cited by 175
When and how to use self (home) and ambulatory blood pressure monitoring.
Pickering, T. G., & White, W. B. (2008) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2008.04.002 · Cited by 153
Weber, M. A., Jamerson, K., Bakris, G. L., Weir, M. R., Zappe, D., Zhang, Y., Dahlof, B., Velazquez, E. J., & Pitt, B. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61343-9 · Cited by 150 · cited 2×
“was equally effective across BMI subgroups and thus offers superior cardiovascular protection in non-obese hypertension, such as in Asian patients.(258) But we do need an RCT involving an Asian population to prove this.”
BackgroundMethodResistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Systemic and Renal-Specific Sympathoinhibition in Obesity Hypertension
Lohmeier, T. E., Iliescu, R., Liu, B., Henegar, J. R., Maric-Bilkan, C., & Irwin, E. D. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.185074 · Cited by 130
McBrien, K., Rabi, D. M., Campbell, N., Barnieh, L., Clement, F., Hemmelgarn, B. R., Tonelli, M., Leiter, L. A., Klarenbach, S. W., & Manns, B. J. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3147 · Cited by 129
Smith, S. M., Gong, Y., Handberg, E., Messerli, F. H., Bakris, G. L., Ahmed, A., Bavry, A. A., Pepine, C. J., & Cooper-DeHoff, R. M. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000051 · Cited by 115
Study of Aldosterone Synthase Inhibition as an Add‐On Therapy in Resistant Hypertension
Karns, A. D., Bral, J. M., Hartman, D., Peppard, T., & Schumacher, C. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12051 · Cited by 104 · cited 1×
“Eplerenone, a more selective mineralocorticoid receptor antagonist without the antiandrogenic effects, was associated with a 10-mmHg reduction in SBP in ABPM, when used as a fourth-line agent at the dose of 50 mg twice daily.(299) The antihypertensive associations of both spironolactone and eplerenone were observed ev…”
MethodAdherence to dietary guidelines and cardiovascular disease risk in the EPIC-NL cohort
Struijk, E. A., May, A. M., Wezenbeek, N. L. W., Fransen, H. P., Soedamah-Muthu, S. S., Geelen, A., Boer, J. M. A., van der Schouw, Y. T., Bueno-de-Mesquita, H. B., & Beulens, J. W. J. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.017 · Cited by 74
Shimbo, D., Levitan, E. B., Booth, J. N., Calhoun, D. A., Judd, S. E., Lackland, D. T., Safford, M. M., Oparil, S., & Muntner, P. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835b6be7 · Cited by 60
Byrd, J. B., & Brook, R. D. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.42 · Cited by 25
Cited by
Wu, C.-Y., Hu, H.-Y., Chou, Y.-J., Huang, N., Chou, Y.-C., & Li, C.-P. (2015) · Medicine · doi:10.1097/md.0000000000002160 · Cited by 207
Kario, K., Shin, J., Chen, C., Buranakitjaroen, P., Chia, Y., Divinagracia, R., Nailes, J., Hoshide, S., Siddique, S., Sison, J., et al. (2019) · The Journal of Clinical Hypertension · doi:10.1111/jch.13652 · Cited by 164
Self-citation(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Self-citationWu, H.-Y., Peng, C.-L., Chen, P.-C., Chiang, C.-K., Chang, C.-J., Huang, J.-W., Peng, Y.-S., Tu, Y.-K., Chu, T.-S., Hung, K.-Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177654 · Cited by 33
Self-citationDong, Y., Jiang, L., Wang, X., Chen, Z., Zhang, L., Zhang, Z., Zheng, C., Kang, Y., Wang, Z., Cao, H., et al. (2020) · The Journal of Clinical Hypertension · doi:10.1111/jch.13838 · Cited by 22
Metadata
- Authors
- Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., Chu, P.-H., Chao, C.-L., Liu, P.-Y., Sung, S.-H., Cheng, H.-M., Wang, K.-L., Li, Y.-H., Chiang, F.-T., Chen, J.-H., Chen, W.-J., Yeh, S.-J., & Lin, S.-J.
- Venue
- Journal of the Chinese Medical Association
- Published
- 2015-01
- Volume
- 78
- Issue
- 1
- Pages
- 1-47
- ISSN
- 1726-4901 (ISSN-L)
- OpenAlex
- W2073453419
- Cited by
- 199
- References
- 122
- FWCI
- 12.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.